StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Morgan Stanley Resumes Pfizer (PFE) at Overweight, Sees Growth Acceleration on Horizon
June 4, 2019 7:40 AM
Morgan Stanley analyst David Risinger resumes coverage on Pfizer (NYSE: PFE) with a Overweight rating and a price ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
New Coverage